title: Kidney function and mortality among patients with left ventricular systolic dysfunction.
abstract: Kidney disease has emerged as a risk factor for mortality in heart failure populations. The objective of this study was to determine the impact of different stages of kidney dysfunction (defined using the Kidney Disease Outcomes Quality Initiative [K/DOQI] classification system) and changes in kidney function on mortality in a cohort of patients with heart failure. A retrospective analysis was conducted of data from the randomized controlled trials Studies of Left Ventricular Dysfunction. A total of 6640 participants with asymptomatic and symptomatic heart failure were studied. Estimated GFR (eGFR) were calculated and then categorized according to the K/DOQI classification system into the following categories: > or =90, 60 to 89, 30 to 59, and 15 to 29 ml/min per 1.73 m2. Reduction in eGFR from baseline was calculated and subsequently categorized according to rate of decline (<5, 5 to 10, 11 to 15, and >15 ml/min per 1.73 m2 per year). Independent of baseline differences, lower levels of eGFR were associated with a higher total mortality compared with those with eGFR > or =90 ml/min (30 to 59 ml/min per 1.73 m2: hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.10 to 1.59, P = 0.004; 15 to 29 ml/min per 1.73 m2: HR 2.54, 95% CI 1.54 to 4.19, P < 0.001). eGFR deteriorated rapidly (>15 ml/min per 1.73 m2 per year) in 12% of participants. This decline was associated with a significant increase in mortality compared with slower decline (<5 ml/min per 1.73 m2 per year), despite adjustments for baseline kidney function, baseline heart failure, or change in heart failure (HR 5.63; 95% CI 4.90 to 6.46; P < 0.0001). The levels of eGFR from the K/DOQI classification system are associated with mortality in a well-characterized heart failure population. Rate of decline in kidney function is a strong predictor of increased mortality in this population, independent of worsening heart failure and baseline kidney function.
authors.affiliation: Division of Internal Medicine, University of British Columbia, Department of Medicine, 620-B, 1081 Burrard Street, Vancouver, BC, Canada, V6Z 1Y6. nakhan@shaw.ca
authors.forename: Nadia A
authors.initials: NA
authors.lastname: Khan
authors.forename: Irene
authors.initials: I
authors.lastname: Ma
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Thompson
authors.forename: Karin
authors.initials: K
authors.lastname: Humphries
authors.forename: Deeb N
authors.initials: DN
authors.lastname: Salem
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Sarnak
authors.forename: Adeera
authors.initials: A
authors.lastname: Levin
mesh_terms: D000328:Adult; D000368:Aged; D004656:Enalapril / Q000494:pharmacology; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D013599:Systole / Q000502:physiology*; D018487:Ventricular Dysfunction, Left / Q000401:mortality / Q000503:physiopathology*
chemical_list: D004656:Enalapril